The role of TNF-α in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

Journal of Lipid Research

Volumn 48, Issue 4, 2007, Pages 751-752

  Popa, Calin ^a   Netea, Mihai G ^a   Van Riel, Piet L C M ^a   Van Der Meer, Jos W M ^a   Stalenhoef, Anton F H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti tumor necrosis factor; Insulin resistance; Lipids; Tumor necrosis factor

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ACETYL COENZYME A CARBOXYLASE; ADALIMUMAB; APOLIPOPROTEIN B; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLESTEROL ESTER TRANSFER PROTEIN; GLUCOSE TRANSPORTER 4; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DRUG RESEARCH; DRUG TARGETING; DYSLIPIDEMIA; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INFLAMMATORY DISEASE; INJURY; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; HUMANS; INFLAMMATION; LIPID METABOLISM; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147126829     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R600021-JLR200     Document Type: Review

References (114)

1. Zachary, T., and M. D. Bloomgarden. 2005. 2nd International Symposium on Triglycerides and HDL: metabolic syndrome. Diabetes Care. 28: 2577-2584.
2. Wolfe, R. R., J. H. Shaw, and M. J. Durkot. 1983. Energy metabolism in trauma and sepsis: the role of fat. Prog. Clin. Biol. Res. 111: 89-109.
3. Douglas, R. G., and J. H. Shaw. 1989. Metabolic response to sepsis and trauma. Br. J. Surg. 76: 115-122.
4. Feingold, K. R., I. Hardardottir, and C. Grunfeld. 1998. Beneficial effects of cytokine induced hyperlipidemia. Z. Ernahrungswiss. 37 (Suppl. 1): 66-74.
5. Butler, S. O., I. F. Btaiche, and C. Alaniz. 2005. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy. 25: 963-976.
6. Koltai, M., E. Minker, and A. Ottlecz. 1972. Inhibition of acute inflammation by hyperlipemia. Experientia. 28: 302-303.
7. Park, Y. B., S. K. Lee, W. K. Lee, C. H. Suh, C. W. Lee, C. H. Lee, C. H. Song, and J. Lee. 1999. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 26: 1701-1704.
8. Svenson, K. L., G. Lundqvist, L. Wide, and R. Hallgren. 1987. Impaired glucose handling in active rheumatoid arthritis: relationship to the secretion of insulin and counter-regulatory hormones. Metabolism. 36: 940-943.
9. Dandona, P., A. Aljada, A. Chauduri, P. Mohanty, and R. Garg. 2005. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 111: 1448-1454.
10. Ross, R. 1999. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340: 115-126.
11. Gimeno, R. E., and L. D. Klaman. 2005. Adipose tissue as an active endocrine organ: recent advances. Curr. Opin. Pharmacol. 5: 122-128.
12. Hotamisligil, G. S., D. L. Murray, L. N. Choy, and B. M. Spiegelman. 1994. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA. 91: 4854-4858.
13. Ridker, P. M. 2003. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 107: 363-369.
14. Ridker, P. M., C. H. Hennekens, J. E. Buring, and N. Rifai. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342: 836-843.
15. Beutler, B., and A. Cerami. 1986. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 320: 584-588.
16. Grunfeld, C., and K. R. Feingold. 1991. Tumour necrosis factor, cytokines and the hyperlipidemia of infection. Trends Endocrinol. Metab. 2: 213-219.
17. Hotamisligil, G. S., N. S. Shargill, and B. M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 259: 87-91.
18. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29 (Suppl. 7): 121-125.
19. Lipsky, P. E., D. M. van der Heijde, E. W. St. Clair, D. E. Furst, F. C. Breedveld, J. R. Kalden, J. S. Smolen, M. Weisman, P. Emery, M. Feldmann, et al. 2000. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343: 1594-1602.
20. Barrera, P., A. van der Maas , A. E. van Ede, B. A. Kiemeney, R. F. Laan, L. B. van de Putte, and P. L. van Riel. 2002. Drug survival, efficacy and toxicity of monotherapy with a fully human antitumor necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis. Rheumatology (Oxford). 41: 430-439.
21. Berbee, J. F., L. M. Havekes, and P. C. Rensen. 2005. Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J. Endotoxin Res. 11: 97-103.
22. Netea, M. G., P. N. M. Demacker, B. J. Kullberg, O. C. Boerman, I. Verschueren, A. F. H. Stalenhoef, and J. W. M. van der Meer. 1996. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe Gram-negative infections. J. Clin. Invest. 97: 1366-1372.
23. Netea, M. G., P. N. M. Demacker, B. J. Kullberg, L. E. H. Jacobs, T. J. G. Verver-Jansen, O. C. Boerman, A. F. H. Stalenhoef, and J. W. M. van der Meer. 1998. Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur. Cytokine. 10: 766-772.
24. Van Doornum, S., G. McColl, and I. P. Wicks. 2002. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 46: 862-873.
25. Svenungsson, E., I. Gunnarsson, G. Z. Fei, I. E. Lundberg, L. Klareskog, and J. Frostegard. 2003. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum. 48: 2533-2540.
26. Jara, L. J., G. Medina, O. Vera-Lastra, and M. C. Amigo. 2006. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun. Rev. 5: 195-201.
27. Boers, M., B. Dijkmans, S. Gabriel, H. Maradit-Kremers, J. O'Dell, and T. Pincus. 2004. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum. 50: 1734-1739.
28. Aggarwal, B. B. 2003. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756.
29. Peraldi, P., G. S. Hotamisligil, W. A. Buurman, M. F. White, and B. M. Spiegelman. 1996. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55TNF receptor and activation of sphingomyelinase. J. Biol. Chem. 271: 13018-13022.
30. Liu, L. S., M. Spelleken, K. Rohring, H. Hauner, and J. Eckel. 1998. Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes. 47: 515-522.
31. Uysal, K. T., S. M. Wiesbrock, and G. S. Hotamisligil. 1998. Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity. Endocrinology. 139: 4832-4838.
32. Sethi, J. K., H. Xu, K. T. Uysal, S. M. Wiesbrock, L. Scheja, and G. S. Hotamisligil. 2000. Characterisation of receptor-specific TNF-alpha functions in adipocyte cell lines lacking type 1 and 2 TNF receptors. FEBS Lett. 469: 77-82.
33. Hotamisligil, G. S., P. Arner, R. L. Atkinson, and B. M. Spiegelman. 1997. Differential regulation of the p80 tumor necrosis factor receptor in human obesity and insulin resistance. Diabetes. 46: 451-455.
34. Blann, A. D., and C. N. McCullum. 1998. Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: no clear relationship with levels of tumor necrosis factor. Inflammation. 22: 483-491.
35. Skoog, T., W. Dichtl, S. Boquist, C. Skoglund-Andersson, F. Carpe, R. Tang, M. G. Bond, U. de Faire, J. Nilsson, P. Eriksson, et al. 2002. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur. Heart J. 23: 376-383.
36. Memon, R. A., C. Grunfeld, A. H. Moser, and K. R. Feingold. 1993. Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology. 132: 2246-2253.
37. Lind, L., and H. Lithell. 1994. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin. Intensive Care. 5: 100-105.
38. Gabay, C., and I. Kushner. 1999. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 340: 448-454.
39. Rossi Fanelli, F., C. Cangiano, M. Muscaritoli, L. Conversano, G. F. Torelli, and A. Cascino. 1995. Tumor-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition. 11: 595-600.
40. Grunfeld, C., M. Pang, W. Doerrler, J. K. Shigenaga, P. Jensen, and K. R. Feingold. 1992. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J. Clin. Endocrinol. Metab. 74: 1045-1052.
41. Sherman, M. L., D. R. Spriggs, K. A. Arthur, K. Imamura, E. Frei III, and D. W. Kufe. 1988. Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol. 6: 344-350.
42. Feingold, K. R., M. Marshall, R. Gulli, A. H. Moser, and C. Grunfeld. 1994. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler. Thromb. 14: 1866-1872.
43. Feingold, K. R., S. Adi, I. Staprans, A. H. Moser, R. Neese, J. A. Verdier, W. Doerrler, and C. Grunfeld. 1990. Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am. J. Physiol. 259: E59-E64.
44. Ryden, M., A. Dicker, V. van Harmelen, H. Hauner, M. Brunnberg, L. Perbeck, F. Lonnqvist, and P. Arner. 2002. Mapping of early signaling events in tumor necrosis factor-alpha -mediated lipolysis in human fat cells. J. Biol. Chem. 277: 1085-1091.
45. Londos, C., D. L. Brasaemle, C. Z. Schultz, D. C. Adler-Wailes, D. M. Levin, A. R. Kimmel, and C. M. Rondinone. 1999. On the control of lipolysis in adipocytes. Ann. N. Y. Acad. Sci. 892: 155-168.
46. Souza, S. C., L. M. de Vargas, M. T. Yamamoto, P. Lien, M. D. Franciosa, L. G. Moss, and A. S. Greenberg. 1998. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor alpha to increase lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 273: 24665-24669.
47. Zimmermann, R., J. G. Strauss, G. Haemmerle, G. Schoiswhol, R. Birner-Gruenberger, M. Riederer, A. Lass, G. Neuberger, F. Eisenhaber, A. Hermetter, et al. 2004. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 306: 1383-1386.
48. Sumida, M., K. Sekiya, H. Okuda, Y. Tanaka, and T. Shiosaka. 1990. Inhibitory effect of tumor necrosis factor on gene expression of hormone sensitive lipase in 3T3-L1 adipocytes. J. Biochem. (Tokyo). 107: 1-2.
49. Kralisch, S., J. Klein, U. Lossner, M. Bluher, R. Paschke, M. Stunvoll, and M. Fasshauer. 2005. Isoproterenol, TNF-alpha, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes. Mol. Cell. Endocrinol. 240: 43-49.
50. Green, A., S. B. Dobias, D. J. Walters, and A. R. Brasier. 1994. Tumor necrosis factor increases the rate of lipolysis in primary cultures of adipocytes without altering levels of hormone-sensitive lipase. Endocrinology. 134: 2581-2588.
51. Gual, P., Y. Le Marchand-Brustel, and J. F. Tanti. 2005. Positive and negative regulation of insulin signalling through IRS-1 phosphorylation. Biochimie. 87: 99-109.
52. Gasic, S., B. Tian, and A. Green. 1999. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J. Biol. Chem. 274: 6770-6775.
53. Ryden, M., E. Arvidsson, L. Blomqvist, L. Perbeck, A. Dicker, and P. Arner. 2004. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem. Biophys. Res. Commun. 318: 168-175.
54. Grunfeld, C., J. A. Verdier, R. Neese, A. H. Moser, and K. R. Feingold. 1988. Mechanisms by which tumor necrosis factor stimulates hepatic fatty acid synthesis in vivo. J. Lipid Res. 29: 1327-1335.
55. Grunfeld, C., M. Soued, S. Adi, A. H. Moser, C. A. Dinarello, and K. R. Feingold. 1990. Evidence for two classes of cytokines that stimulate hepatic lipogenesis: relationships among tumor necrosis factor, interleukin-1 and interferon-alpha. Endocrinology. 127: 46-54.
56. Tripp, R. J., A. Tabares, H. Wang, and S. Lanza-Jacoby. 1993. Altered hepatic production of apolipoproteins B and E in the fasted septic rat: factors in the development of hypertriglyceridemia. J. Surg. Res. 55: 465-472.
57. Memon, R. A., W. M. Holleran, A. H. Moser, T. Seki, Y. Uchida, J. Fuller, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 1998. Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin. Arterioscler. Thromb. Vasc. Biol. 18: 1257-1265.
58. Auge, N., A. Negre-Salvayre, R. Salvayre, and T. Levade. 2000. Sphingomyelin metabolites in vascular cell signaling and atherogenesis. Prog. Lipid Res. 39: 207-229.
59. Feingold, K. R., A. S. Pollock, A. H. Moser, J. K. Shigenaga, and C. Grunfeld. 1995. Discordant regulation of proteins of cholesterol metabolism during the acute phase response. J. Lipid Res. 36: 1474-1482.
60. Memon, R. A., I. Shechter, A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 1997. Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. J. Lipid Res. 38: 1620-1629.
61. Ettinger, W. H., V. K. Varna, M. Sorci-Thomas, J. S. Parks, R. C. Sigmon, T. K. Smith, and R. B. Verdery. 1994. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler. Thromb. 14: 8-13.
62. De Fabiani, E., N. Mitro, A. C. Anzulovich, A. Pinelli, G. Galli, and M. Crestani. 2001. The negative effects of bile acids and tumor necrosis factor-α on the transcription of cholesterol 7α-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4. J. Biol. Chem. 276: 30708-30716.
63. Memon, R. A., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2001. In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. Potential role of hepatocyte nuclear factor-1. J. Biol. Chem. 276: 30118-30126.
64. Stopeck, A. T., A. C. Nicholson, F. P. Mancini, and D. P. Haijar. 1993. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J. Biol. Chem. 268: 17489-17494.
65. Feingold, K. R., R. M. Krauss, M. Pang, W. Doerrler, P. Jensen, and C. Grunfeld. 1993. The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J. Clin. Endocrinol. Metab. 76: 1423-1427.
66. Arbibe, L., D. Vial, I. Rosinski-Chupin, N. Havet, M. Huerre, B. B. Vargaftig, and L. Tourqui. 1997. Endotoxin induces expression of type II phospholipase A2 in macrophages during acute lung injury in guinea pigs. J. Immunol. 159: 391-400.
67. Pruzanski, W., P. Vadas, and J. Browning. 1993. Secretory pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. J. Lipid Mediat. 8: 161-167.
68. Ohashi, R., H. Mu, X. Wang, Q. Yao, and C. Chen. 2005. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. Q. J. Med. 98: 845-856.
69. Linsel-Nitschke, P., and A. R. Tall. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat. Rev. Drug Discov. 4: 193-205.
70. Duffy, D., and D. J. Rader. 2006. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation. 113: 1140-1150.
71. Khovidhunkit, W., A. H. Moser, J. K. Shigenaga, C. Grunfeld, and K. R. Feingold. 2001. Regulation of scavenger receptor class B type I in master liver and Hep3B cells by endotoxin and cytokines. J. Lipid Res. 42: 1636-1644.
72. Ettinger, W. H., L. D. Miller, J. J. Albers, T. K. Smiths, and J. S. Parks. 1990. Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin:cholesterol acyltransferase in cynomolgus monkeys. J. Lipid Res. 31: 1099-1107.
73. Kuivenhoven, J. A., H. Pritchard, J. Hill, J. Frochlich, G. Assmann, and J. Kastelein. 1997. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38: 191-205.
74. Hardardottir, I., A. H. Moser, J. Fuller, C. Fielding, K. R. Feingold, and C. Grunfeld. 1996. Endotoxin and cytokines decrease serum levels and extra hepatic protein and mRNA levels of cholesteryl ester transfer protein in Syrian hamsters. J. Clin. Invest. 97: 2585-2592.
75. Inazu, A., M. L. Brown, C. B. Hesler, L. B. Agellon, J. Koizumi, K. Takata, Y. Maruhama, H. Mabuchi, and A. R. Tall. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323: 1234-1238.
76. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
77. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwindermann, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105: 2159-2165.
78. Hardardottir, I., S. T. Kunitake, A. H. Moser, W. Doerrler, J. H. Rapp, C. Grunfeld, and K. R. Feingold. 1994. Endotoxin and cytokines increase hepatic mRNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J. Clin. Invest. 94: 1304-1309.
79. Hardardottir, I., A. H. Moser, R. Memon, C. Grunfeld, and K. R. Feingold. 1994. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 13: 161-166.
80. Hoffman, G. S., and E. P. Benditt. 1983. Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J. Clin. Invest. 71: 926-934.
81. Kumon, Y., Y. Nakauchi, T. Suehiro, T. Shiinoki, N. Tanimoto, M. Inoue, T. Nakamura, K. Hashimoto, and J. D. Sipe. 2002. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid. 9: 160-164.
82. McMahon, M., J. Grossman, J. FitzGerald, E. Dahlin-Lee, D. J. Wallace, B. Y. Thong, H. Badsha, K. Kalunian, C. Charles, M. Navab, et al. 2006. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54: 2541-2549.
83. Schreyer, S. A., J. J. Peschon, and R. C. Le Boeuf. 1996. Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J. Biol. Chem. 271: 26174-26178.
84. Gerbod-Giannone, M. C., Y. Li, A. Holleboom, S. Han, L. C. Hsu, I. Tabas, and A. R. Tall. 2006. TNF-{alpha} induces ABCA1 through NF-{kappa}B in macrophages and in phagocytes ingesting apoptotic cells. Proc. Natl. Acad. Sci. USA. 103: 3112-3117.
85. Ohta, H., H. Wada, T. Niwa, H. Kirii, N. Iwamoto, H. Fujii, K. Saito, K. Sekikawa, and M. Seishima. 2005. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in apoE-deficient mice. Atherosclerosis. 180: 11-17.
86. Schreyer, S. A., C. M. Vick, and R. C. LeBoeuf. 2002. Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J. Biol. Chem. 277: 12364-12368.
87. Popa, C., M. G. Netea, T. Radstake, J. W. Van der Meer, A. F. Stalenhoef, P. L. van Riel, and P. Barrera. 2005. Influence of antitumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 64: 303-305.
88. Vis, M., M. T. Nurmohamed, G. Wolbink, A. E. Voskuyl, M. de Koning, R. J. van de Stadt, J. W. R. Twisk, B. A. C. Dijkmans, and W. F. Lems. 2005. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J. Rheumatol. 32: 252-255.
89. Irace, C., G. Mancuso, E. Fiaschi, A. Madia, G. Sesti, and A. Gnasso. 2004. Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis. 177: 113-118.
90. Yudkin, J. S., C. D. Stehouwer, J. J. Emeis, and S. W. Coppack. 1999. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19: 972-978.
91. Crook, M. A., P. Tutt, and J. C. Pickup. 1993. Elevated serum sialic acid concentration in NIDDM and its relationship to blood pressure and retinopathy. Diabetes Care. 16: 57-60.
92. Pickup, J. C., M. B. Mattock, G. D. Chusney, and D. Burt. 1997. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40: 1286-1292.
93. Pradhan, A. D., J. E. Manson, N. Rifai, J. E. Buring, and P. M. Ridker. 2001. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. J. Am. Med. Assoc. 286: 327-334.
94. Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95: 2409-2415.
95. Ziccardi, P., F. Nappo, G. Giugliano, K. Esposito, R. Martella, M. Ciuffi, F. D'Andrea, A. M. Molinari, and D. Giugliano. 2002. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 105: 804-809.
96. Hotamisligil, G. S., and B. M. Spiegelman. 1994. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 43: 1271-1278.
97. Hofmann, C., K. Lorenz, S. S. Braithwaite, J. R. Colca, B. J. Palazuk, G. S. Hotamisligil, and B. M. Spiegelman. 1994. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology. 134: 264-270.
98. Uysal, K. T., S. M. Wiesbrock, M. W. Marino, and G. S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 389: 610-614.
99. Saghizadeh, M., J. M. Ong, W. T. Garvey, R. R. Henry, and P. A. Kern. 1996. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J. Clin. Invest. 97: 1111-1116.
100. Gao, Z., D. Hwang, F. Bataille, M. Lefevre, D. York, M. J. Quon, and J. Ye. 2002. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J. Biol. Chem. 277: 48115-48121.
101. Stephens, J. M., and P. H. Pekala. 1991. Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J. Biol. Chem. 266: 21839-21845.
102. Zhang, B., J. Berger, E. Hu, D. Szalkowski, S. White-Carrington, B. M. Spiegelman, and D. E. Moller. 1996. Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha. Mol. Endocrinol. 10: 1457-1466.
103. Bruun, J. M., A. S. Lihn, C. Verdich, S. B. Pedersen, S. Toubro, P. Astrup, and B. Richelsen. 2003. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am. J. Physiol. Endocrinol. Metab. 285: E527-E533.
104. Matsuzawa, Y., T. Funahashi, S. Kihara, and I. Shimomura. 2004. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 24: 29-33.
105. Ahima, R. S., and J. S. Flier. 2000. Leptin. Annu. Rev. Physiol. 62: 413-437.
106. Sica, A., J. M. Wang, F. Colotta, E. Dejana, A. Mantovani, J. J. Oppenheim, C. G. Larsen, C. O. Zachariae, and K. Matsushima. 1999. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J. Immunol. 144: 3034-3038.
107. van der Poll, T., J. A. Romijn, E. Endert, J. J. Borm, H. R. Buller, and H. P. Sauerwein. 1991. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am. J. Physiol. 261: E457-E465.
108. Kubaszek, A., J. Pihlajamaki, V. Komarovski, V. Lindi, J. Lindstrom, J. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen- Kiukaanniemi, et al. 2003. Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes. 52: 1872-1876.
109. Ofei, F., S. Hurel, J. Newkirk, M. Sopwith, and R. Taylor. 1996. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 45: 881-885.
110. Bernstein, L. E., J. Berry, S. Kim, B. Canavan, and S. K. Grinspoon. 2006. Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166: 902-908.
111. Yazdani-Biuki, B., H. Stelzl, H. P. Brezinschek, J. Hermann, T. Mueller, P. Krippl, W. Graninger, and T. C. Wascher. 2004. Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with anti-TNF-α antibody infliximab. Eur. J. Clin. Invest. 34: 641-642.
112. Huvers, F. C., C. Popa, M. G. Netea, F. H. J. van den Hoogen, and C. J. Tack. 2007. Improved insulin sensitivity by anti-TNF-α antibody treatment in patients with rheumatic diseases. Ann. Rheum. Dis. In press.
113. Jain, M. K., and P. M. Ridker. 2005. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4: 977-987.
114. Lehrke, M., and M. A. Lazar. 2005. The many faces of PPARgamma. Cell. 123: 993-999.